IRST Dino Amadori IRCCS

Lines of Research

IRST’s research activity is oriented along four lines approved by the Ministry of Health.
Research Line 1: Appropriateness, outcomes, drug value, and functional organisational models for continuity of diagnostic-therapeutic pathways in oncology.
Research Line 2: Innovative therapies, phase I-III, and therapeutic strategy trials based on preclinical models, onco-immunological mechanisms, and nanovectors.
Research Line 3: Precision medicine, gender, ethnicity and 'geroscience': molecular genetic mechanisms in the development, characterisation, and therapy of cancer.
Research Line 4: Genetics and environment in cancer development, progression, and inhibitory mechanisms. Exposomics, primary and secondary prevention.
IRST’s research activities were implemented with a view towards tightening its collaboration with AUSL of Romagna within the Comprehensive Cancer Care and Research Network (CCCRN), with particular reference to:
● Clinical trials, with further enhancement of the Phase I Facility and translational activities studying new biomarkers;
● personalised medicine using omics and NGS, mutational reporting, molecular tumour board, liquid biopsy, metabolomics;
● Avidination for Radionuclide Therapy in clinical occult breast cancer;
● Design, implementation, and testing of Advanced Therapy Medicinal Products (ATMPs), vaccines, and CAR-T therapies;
● Artificial intelligence, digital health, and big data.


In 2021, the self-certification process as a Contract Research Organization (CRO) at AIFA was completed following the regulatory requirements (DM 15/11/2019) for data management activities, monitoring, and statistical analysis of clinical trial data. IRST’s CRO adopted a regulation approved by the Board of Directors: a Flow Chart and Operational Procedures that promote and ensure adequate quality levels of clinical trials following the principles of Good Clinical Practice (GCP) and giving support to IRST researchers and other Italian or foreign sponsoring bodies in the management of clinical research.  


Outcome Research studies the final results (outcomes) of patient care and management to systematically assess the quality, efficiency, and effectiveness of care, together with an economic evaluation from a Value-Based Health Care perspective, i.e. maximising value for the patient in terms of health outcomes and safeguarding the sustainability of the health system in terms of economics. It is well known that measurement represents the elective tool to understand phenomena and promote their improvement; thanks to the significant amount of clinical and administrative data generated along the care pathways, IRST can study them in depth. In this way, data becomes an element of both planning and research. The continuous study of data collected along the care pathways means internally better To this end, IRST is carrying out numerous projects financed by external bodies for more than 1 million euros.